Suppr超能文献

两个患有常染色体隐性IIA型皮肤松弛症的墨西哥混血儿身上存在ATP6V0A2基因突变。

ATP6V0A2 mutations present in two Mexican Mestizo children with an autosomal recessive cutis laxa syndrome type IIA.

作者信息

Bahena-Bahena D, López-Valdez J, Raymond K, Salinas-Marín R, Ortega-García A, Ng B G, Freeze H H, Ruíz-García M, Martínez-Duncker I

机构信息

Human Glycobiology Laboratory, Science Faculty, Morelos State Autonomous University, Cuernavaca, Mexico.

Department of Genetics, Centenario Miguel Hidalgo Hospital, Aguascalientes, Mexico.

出版信息

Mol Genet Metab Rep. 2014 Apr 25;1:203-212. doi: 10.1016/j.ymgmr.2014.04.003. eCollection 2014.

Abstract

Patients with ARCL-IIA harbor mutations in ATP6V0A2 that codes for an organelle proton pump. The ARCL-IIA syndrome characteristically presents a combined glycosylation defect affecting -linked and -linked glycosylations, differentiating it from other cutis laxa syndromes and classifying it as a Congenital Disorder of Glycosylation (ATP6V0A2-CDG). We studied two Mexican Mestizo patients with a clinical phenotype corresponding to an ARCL-IIA syndrome. Both patients presented abnormal transferrin (-linked) glycosylation but Patient 1 had a normal ApoCIII (-linked) glycosylation profile. Mutational screening of ATP6V0A2 using cDNA and genomic DNA revealed in Patient 1 a previously reported homozygous nonsense mutation c.187C>T (p.R63X) associated with a novel clinical finding of a VSD. In Patient 2 we found a homozygous c.2293C>T (p.Q765X) mutation that had been previously reported but found that it also altered RNA processing generating a novel transcript not previously identified (r.2176_2293del; p.F726Sfs*10). This is the first report to describe Mestizo patients with molecular diagnosis of ARCL-IIA/ATP6V0A2-CDG and to establish that their mutations are the first to be found in patients from different regions of the world and with different genetic backgrounds.

摘要

患有II型常染色体隐性遗传的先天性皮肤松弛症(ARCL-IIA)的患者,其ATP6V0A2基因发生突变,该基因编码一种细胞器质子泵。ARCL-IIA综合征的特征是出现一种影响N-连接和O-连接糖基化的联合糖基化缺陷,这使其有别于其他皮肤松弛综合征,并将其归类为先天性糖基化障碍(ATP6V0A2-CDG)。我们研究了两名具有与ARCL-IIA综合征相对应临床表型的墨西哥梅斯蒂索人患者。两名患者均表现出异常的转铁蛋白(N-连接)糖基化,但患者1的载脂蛋白CIII(O-连接)糖基化谱正常。使用cDNA和基因组DNA对ATP6V0A2进行突变筛查,在患者1中发现了一个先前报道的纯合无义突变c.187C>T(p.R63X),该突变与室间隔缺损这一新的临床发现相关。在患者2中,我们发现了一个先前报道过的纯合c.2293C>T(p.Q765X)突变,但发现它也改变了RNA加工过程,产生了一种先前未鉴定的新转录本(r.2176_2293del;p.F726Sfs*10)。这是第一份描述对ARCL-IIA/ATP6V0A2-CDG进行分子诊断的梅斯蒂索人患者的报告,并证实他们的突变是首次在来自世界不同地区且具有不同遗传背景的患者中发现。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e854/5121299/e94d8b3cf82f/gr3.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验